PMC

Lesion numbers at Weeks 24 and 48. A) New or newly-enlarging T2 lesions ^aBased on negative binomial regression analysis, adjusted baseline T2 lesion number. The data for 48 weeks has been published previously []. CI = confidence interval. B) New T1 hypointense lesions compared to baseline ^bBased on mean number of new lesions only and p value based on multiple logit regression, adjusted for baseline number of T1 lesions. The data for 48 weeks has been published previously []. SE = standard error. C) Gd+ lesions ^cBased on mean number of lesions only and p value based on multiple logit regression, adjusted for baseline number of Gd+ lesions. Gd+ = gadolinium-enhancing; SE = standard error.

NEDA proportions. A) Baseline to Week 48. B). Baseline to Week 24. C). Weeks 24–48. ORs are shown with 95% confidence intervals in parentheses. ^aDefined as absence of both clinical (no relapses and no onset of 12-week confirmed disability progression over the interval) and MRI (no gadolinium-enhancing lesions and no new or newly-enlarging T2 hyperintense lesions) disease activity; data from patients with complete MRI results during the time interval were used for analysis of MRI disease activity. NEDA = No evidence of disease activity; MRI = magnetic resonance imaging; OR = odds ratio.